Rankings
▼
Calendar
EVMN Q1 2024 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena
EVMN
Evommune, Inc.
$319M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$7M
Gross Profit
$7M
96.1% margin
Operating Income
-$4M
-53.6% margin
Net Income
-$3M
-39.8% margin
EPS (Diluted)
$-0.09
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$0
← FY 2024
All Quarters
Q2 2024 →